Parexel Intl Cp (PRXL) 68.70 $PRXL IMPORTANT IN

Parexel Intl Cp (PRXL) 68.70 $PRXL

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of PAREXEL International Corporation
BusinessWire - Thu Sep 01, 11:02AM CDT
Khang & Khang LLP (the "Firm" announces that it is investigating claims against PAREXEL International Corporation ("PAREXEL" or the "Company" (Nasdaq: PRXL) concerning possible violations of federal securities laws.
PRXL: 68.70 (+0.36)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PAREXEL International Corporation (PRXL)
ACCESSWIRE - Thu Sep 01, 9:02AM CDT
NEW YORK, NY / ACCESSWIRE / September 1, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities PAREXEL International Corporation ("PARXEL" or the "Company" (NASDAQ: PRXL). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
PRXL: 68.70 (+0.36)

PAREXEL International to Present at Wells Fargo Healthcare Conference
BusinessWire - Thu Sep 01, 8:30AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) announced today it will be presenting at the Wells Fargo Healthcare Conference on Wednesday September 7, 2016 in Boston. Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 9:20a.m. ET.
PRXL: 68.70 (+0.36), WFC: 50.55 (+0.12)

SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of PAREXEL International Corporation and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Aug 31, 6:41PM CDT
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against PAREXEL International Corporation ("PAREXEL" or the "Company" (Nasdaq: PRXL) concerning possible violations of federal securities laws.
PRXL: 68.70 (+0.36)

INVESTOR ALERT: Investigation of PAREXEL International Corporation Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Aug 31, 5:45PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of PAREXEL International Corporation ("PAREXEL" or the "Company" (NASDAQ: PRXL) concerning the Company and its officers' possible violations of federal securities laws.
PRXL: 68.70 (+0.36)

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against PAREXEL International Corporation and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Aug 31, 4:58PM CDT
Goldberg Law PC announces that it is investigating PAREXEL International Corporation ("PAREXEL" or the "Company" (Nasdaq: PRXL) concerning possible violations of federal securities laws.
PRXL: 68.70 (+0.36)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of PAREXEL International Corporation
BusinessWire - Wed Aug 31, 4:08PM CDT
Levi & Korsinsky announces it has commenced an investigation of PAREXEL International Corporation (NASDAQ RXL) ("PAREXEL" concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
PRXL: 68.70 (+0.36)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of PAREXEL Corporation - PRXL
PR Newswire - Wed Aug 31, 3:46PM CDT
Pomerantz LLP is investigating claims on behalf of investors of PAREXEL Corporation ("PAREXEL" or the "Company" (NASDAQ: PRXL). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
PRXL: 68.70 (+0.36)

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against PAREXEL International Corporation - PRXL
BusinessWire - Wed Aug 31, 2:27PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of PAREXEL International Corporation (NASDAQ RXL) resulting from allegations that PAREXEL may have issued materially misleading business information to the investing public.
PRXL: 68.70 (+0.36)

SmarTrend Watching for Potential Pullback in Shares of Parexel International After 2.14% Gain
Comtex SmarTrend(R) - Mon Aug 29, 4:22PM CDT
Parexel International (NASDAQ RXL) traded in a range yesterday that spanned from a low of $68.80 to a high of $70.24. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $69.98 on volume of 178,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRXL: 68.70 (+0.36)

PAREXEL's Head of BioPharm Unit Named to the 2016 PharmaVOICE 100
BusinessWire - Mon Aug 15, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that PharmaVOICE magazine selected Ubavka DeNoble, MD, Corporate Vice President, as one of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2016 issue of PharmaVOICE, recognizes Dr. DeNoble for her innovative thinking, passion and fervor for the industry, and dedication to mentoring the next generation of leaders.
PRXL: 68.70 (+0.36)

PAREXEL International (PRXL) Q4 Earnings Beat, Up Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:12AM CDT
PAREXEL International (PRXL) reported fourth-quarter fiscal 2016 adjusted earnings per share of 94 cents.
PRXL: 68.70 (+0.36), ABCO: 42.22 (+0.04), HQY: 33.55 (+1.05), PRAH: 50.38 (-0.18)

PAREXEL International Reports Fourth Quarter and Fiscal Year 2016 Results
BusinessWire - Wed Aug 03, 3:27PM CDT
--GAAP diluted earnings per share of $0.83, up 36.1%; adjusted earnings per share of $0.94, up 19.0%
PRXL: 68.70 (+0.36)

Healthcare Q2 Earnings Lineup for Aug 3: HUM, CRL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:36AM CDT
The Medical sector is expected to deliver 5.4% earnings growth on 10.5% higher revenues in the second quarter.
PRXL: 68.70 (+0.36), EVHC: 22.18 (+0.73), CRL: 84.42 (+0.82), HUM: 177.33 (+0.80)

PAREXEL Appoints Four Executives to Senior Leadership Team
BusinessWire - Mon Aug 01, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Review Committee:
PRXL: 68.70 (+0.36)

PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016
BusinessWire - Mon Jun 20, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will discuss key issues facing the industry at the 52nd Annual Drug Information Association (DIA) meeting, held from June 26-30, 2016 in Philadelphia.
PRXL: 68.70 (+0.36)

PAREXEL Invites Public to Listen to Live Webcast of Investor Day Presentations on June 30
BusinessWire - Wed Jun 15, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day presentations on Thursday, June 30, 2016, from 9:00 a.m. to 12:00 p.m. EDT.
PRXL: 68.70 (+0.36)

PAREXEL Announces Master Services Agreement with Pfizer
BusinessWire - Fri Jun 10, 1:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has signed a services agreement with Pfizer Inc. Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.
PRXL: 68.70 (+0.36)

PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from the American Business Awards
BusinessWire - Thu Jun 02, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year - Pharmaceuticals in the 14th Annual American Business Awards(SM). The judges awarded PAREXEL a Gold Stevie(R) Award and recognized the Company's investments in innovation and expanded capabilities across the drug development continuum in 2015 as specifics for the accolade.
PRXL: 68.70 (+0.36)